ClinicalTrials.Veeva

Menu

Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries

G

Gachon University Gil Medical Center

Status and phase

Unknown
Phase 4

Conditions

Coronary Artery Disease

Treatments

Device: SeQuent® Please Drug-eluting balloon

Study type

Interventional

Funder types

Other

Identifiers

NCT01903902
DEB-ONLY

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of paclitaxel-eluting balloon (SeQuent® Please) for treatment of lesions in native small coronary arteries.

Full description

Drug-eluting balloon (DEB) have emerged as a potential alternative to overcome the limitations of drug-eluting stents such as restenosis or stent thrombosis.

DEB angioplasty is proven to be effective clinically for the treatment of in-stent restenosis. However, DEB for de novo lesions, especially in small vessels is less studied.

The purpose of this study is to evaluate the efficacy and safety of paclitaxel-eluting balloon (SeQuent® Please) for treatment of lesions in native small coronary arteries.

Enrollment

1,000 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 19 years
  • Patients who are appropriate for percutaneous coronary intervention using drug-eluting balloon in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, lesion length < 25 mm)
  • Informed consent

Exclusion criteria

  • Chronic total obstruction lesion
  • Severe calcified lesion
  • Left main coronary lesion
  • Lesion having intravascular thrombus
  • Shock status from any cause including cardiogenic shock
  • Left ventricular ejection fraction < 30%
  • Need for coronary artery bypass surgery
  • Allergic reaction for paclitaxel
  • Severe allergic for contrast agent (Visipaque) or statin
  • Pregnancy, breastfeeding or Expectation for pregnancy in women of childbearing age

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

1,000 participants in 1 patient group

Drug-eluting balloon
Experimental group
Description:
Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter \> 2.25 mm and ≤ 2.75 mm)
Treatment:
Device: SeQuent® Please Drug-eluting balloon

Trial contacts and locations

1

Loading...

Central trial contact

Woong Chul Kang, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems